Table 3 Baseline medication profiles of the cohort.

From: Renal protective effect of sacubitril/valsartan in patients with heart failure

Characteristics Total Sacubitril/valsartan Valsartan P value
n = 274 n = 137 n = 137
Beta blockers, n(%) 131(47.8) 111(81.0) 20(14.6) < 0.01
Dihydropiridine CCB, n(%) 47(17.2) 25(18.3) 22(16.1) 0.63
Non-dihydropiridine CCB, n(%) 10(3.7) 6(4.4) 4(2.9) 0.52
NTG, n(%) 22(8.0) 19(13.9) 3(2.2) < 0.01
Amiodarone, n(%) 26(9.5) 24(17.5) 2(1.5) < 0.01
Aspirin, n(%) 69(25.2) 52(38.0) 17(12.4) < 0.01
Clopidogrel, n(%) 60(21.9) 55(40.2) 5(3.7) < 0.01
Rivaroxaban, n(%) 29(10.6) 26(19.0) 3(2.2) < 0.01
Warfarin, n(%) 6(2.2) 3(2.2) 3(2.2) 1.00
Febuxostat, n(%) 40(14.6) 36(26.3) 4(2.9) < 0.01
Fibrates, n(%) 9(3.3) 7(5.2) 2(1.5) 0.17
Statin, n(%) 106(38.7) 88(64.2) 18(13.1) < 0.01
Ivabradine, n(%) 17(6.2) 17(12.4) 0 < 0.01
  1. CCB calcium channel blocker, NTG nitroglycerin.